Evaluation of the Performance of Novel Aβ Isoforms as Theragnostic Markers in Alzheimer’s Disease: From the Cell to the Patient

Publisher： Karger

E-ISSN： 1660-2862|10|1-4|138-140

ISSN： 1660-2854

Source： Neurodegenerative Diseases, Vol.10, Iss.1-4, 2012-02, pp. : 138-140

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of a Novel Yeast Cell-Based System for Studying the Aggregation of Alzheimer’s Disease-Associated Aβ Peptides in vivo

By  

Neurodegenerative Diseases, Vol. 4, Iss. 2-3, 2007-06 ,pp. : 136-147

Karger

Access to resources Recommend Favorite

Aβ Immunotherapy: Lessons Learned for Potential Treatment of Alzheimer’s Disease

By  

Neurodegenerative Diseases, Vol. 2, Iss. 5, 2006-02 ,pp. : 255-260

Karger

Access to resources Recommend Favorite

Intraneuronal Aβ Accumulation, Amyloid Plaques, and Synapse Pathology in Alzheimer’s Disease

By  

Neurodegenerative Diseases, Vol. 10, Iss. 1-4, 2012-01 ,pp. : 56-59

Karger

Access to resources Recommend Favorite

Acetylcholinesterase Variants in Alzheimer’s Disease: From Neuroprotection to Programmed Cell Death

By  

Neurodegenerative Diseases, Vol. 7, Iss. 1-3, 2010-02 ,pp. : 60-63

Karger

Access to resources Recommend Favorite

Passive Immunization of the Aβ42(43) C-Terminal-Specific Antibody BC05 in a Mouse Model of Alzheimer’s Disease

By  

Neurodegenerative Diseases, Vol. 2, Iss. 1, 2005-08 ,pp. : 36-43

Karger

Access to resources Recommend Favorite